To: 512e 512e 5.1.2e @rivm.nl]
Sent: Wed 11/18/2020 8:46:53 AM

Subject: FW: FOR YOUR REVIEW: Updated forecasts of COVID-19 in the EU/EEA and UK

Received: Wed 11/18/2020 8:46:53 AM

Dear 5.1.2e

Thanks for sending the updated projections.

Comments: It is an enormous effort to pull all this together. I find it very impressive to see that one model can be used to make projections for many different countries. In general, the time course of normalized number of contacts must be incorrect for almost all countries, a return to values near 1 in October would imply that second waves would grow almost as fast as the first waves, whereas the observed growth rates in the second wave have been substantially lower as compared to the first wave.

Specific comments about the Netherlands, in Figure 1, the control measures don't match the actual situation (not sure what went wrong and where, perhaps the interpretation into the few available categories is very difficult). In Figure 2 the effect of non-pharmaceutical interventions on contacts don't make sense, they do not agree with estimates of the effective reproduction number and they don not agree with the outcome of our contact surveys. In Figure 3h there is a very poor fit to the data for the Netherlands. When you make predictions for many different countries, predictions for a few countries will be far off, in this case the Netherlands is among these few.

There are several modelling initiatives and projections in the NL (calculation of effective reproduction numbers; projections for IC admissions, hospital admissions, cases in nursing homes). We recently got the results of our contact surveys before and during control measures accepted for publication in Eurosurveillance, <a href="https://www.medrxiv.org/content/10.1101/2020.05.18.20101501v2">https://www.medrxiv.org/content/10.1101/2020.05.18.20101501v2</a>. These contact surveys are in addition to the comix study in the NL.

Best wishes.

5.1.2e

```
From: 5.1.2e 5.1.2e 5.1.2e 5.1.2e
Sent: vrijdag 13 november 2020 15:37
To:
                                                                    @ecdc.europa.eu>; 5.1.2e
                                      5.1.2e 5.1.2e <
                                                          5.1.2e
                                                                   @sam.lt>; 5.1.2e 5.1.2e <
                                                                                                 5.1.2e
               @elisabethinen.or.at>;
                                                                                                           @vzbb.sk>; 126
  5.1.2e 5.1.2e 5.1.2e <
                                              @chl.lu>; 5.1.2e 5.1.2e <
                                                                                @iss.it>;
                @santepubliquefrance.fr>; 5.1.2e <
      5.1.2e
                                                                   @fhi.no>; 5.1.2e
                                                                                     5.1.2e
                                                                                                             @gov.mt>;
           5.1.2e < 5.1.2e @landlaeknir.is>; 5.1.2e <
                                                                  5.1.2e @rki.de>; 5.1.2e 5.1.2e
                                                                                                5.1.2e @nijz.si>; 5.1.2e
  5.1.2e 5.1.2e <
                                  @hzjz.hr>; 5.1.2e 6.12e < 5.1.2e @szu.cz>; 5.1.2e 5.1.2e
           @mphs.moh.gov.cy>; 5.1.2e 5.1.2e < 5.1.2e @hpsc.ie>; 5.1.2e 5.1.2e <
                                                                                               @insa.min-saude.pt>;
  5.1.2e 5.1.2e <5.1.2e @ssi.dk>; 5.1.2e
                                                                @spkc.gov.lv>; 5.1.2e 5.1.2e <
                                       5.1.2e <
                                                    5.1.2e
  5.1.2e 5.1.2e < 5.1.2e @tcd.ie>;
                                        5.1.2e
                                                             < 5.1.2e @pzh.gov.pl>; 5.1.2e < 5.1.2e <
                                                                                                      5.1.2e @thl.fi>;
 5.1.2e 5.1.2e 5.1.2e < 5.1.2e @msssi.es>; 5.1.2e 5.1.2e < 5.1.2e
                                                                   @folkhalsomyndigheten.se>; 5.1.2e 5.1.2e
            @rivm.nl>; 5.1.2e 5.1.2e < 5.1.2e @med.uoa.gr>; 5.1.2e 5.1.2e < 5.1.2e
                                                                                         @rivm.nl>; 5.1.2e 5.1.2e 5.1.2e
        5.1.2e @sciensano.be>; 5.1.2e 5.1.2e < 5.1.2e
                                                                     @nnk.gov.hu>; 5.1.2e 124
    5.1.2e @who.int>; 5.1.2e 5.1.2e 5.1.2e < 5.1.2e @yahoo.com>; 5.1.2e 5.1.2e <
                                                                                      5.1.2e
                                                                                               @ijzcg.me>
                         @nnk.gov.hu>; 5.1.2e 5.1.2e < 5.1.2e @agihas.lv>;
Cc: 5.1.2e 5.1.2e < 5.1.2e
                                                                            5.1.2e
                                              @thl.fi>; 5.1.2e 5.1.2e <
                                                                          5.1.2e
 5.1.2e
                                                                                    @santepubliquefrance.fr>; 5.1.2e 5.1.2e
 5.1.2e < 5.1.2e @arsnorte.min-saude.pt>; 5.1.2e < 5.1.2e <
                                                             @hse.ie>;
         5.1.2e < 5.1.2e @mh.government.bg>; 5.1.2e 5.1.2e < 5.1.2e @mphs.moh.gov.cy>; 5.1.2e 5.1.2e
                                                            @jfmed.uniba.sk>; 5.1.2e 5.1.2e <
                                5.1.2e <
            @nijz.si>;
                                                                                                         @bkus.lv>:
  5.1.2e 5.1.2e
                                  @inmi.it>; 5.1.2e 5.1.2e <
                                                            5.1.2e @terviseamet.ee>; 5.1.2e 5.1.2e 5.1.2e <5.1.2e @ssi.dk>;
                          5.1.2e
                                     @sam.lt>; 5.1.2e 5.1.2e <
                                                                         @folkhalsomyndigheten.se>; 5.1.2e 5.1.2e
            5.1.2e <
   5.1.2e @fhi.no>; 5.1.2e 5.1.2e
                                   5.1.2e < 5.1.2e @isciii.es>; 5.1.2e <
                                                                               5.1.2e
                                                                                        @gov.mt>; 5.1.2e 5.1.2e
            @rki.de>; 5.1.2e 5.1.2e < 5.1.2e
                                                  @sciensano.be>; 5.1.2e 5.1.2e
                                                                                     < 5.1.2e @pzh.gov.pl>;
               5.1.2e < 5.1.2e @landlaeknir.is>;
                                                           5.1.2e <
                                                 5.1.2e
                                                                                        @hzjz.hr>; 5.1.2e 5.1.2e
              @ec.europa.eu>; 5.1.2e 5.1.2e
      5.1.2e
                                                            @ecdc.europa.eu>; 5.1.2e 5.1.2e
             @ecdc.europa.eu>; 5.1.2e <
                                                          @ecdc.europa.eu>; PHE Manager
              5.1.2e @ecdc.europa.eu>
```

Subject: RE: FOR YOUR REVIEW: Updated forecasts of COVID-19 in the EU/EEA and 5.1.2e

Dear 5.1.2e


I hope and assume you already ran this report past our modelling group (per 5.1.2e 5.1.2e ).

After quickly going through the report, I notice that ECDC forecasts are really not compatible with our own. Probably due to assumptions not in line with the actual situation.

This may explain also why in Figure 1, the actual number of reported cases in the last month is far above the projection.

On the other hand, the normalized numbers of contacts returning to values around 1 for the Netherlands, which would lead to higher number of projected cases, is contradicted by actual measurements.

Best regards, 5.1.2e 5.12e 5.12e 5.12e



 $\textbf{Subject:} \ \textbf{FOR YOUR REVIEW:} \ \textbf{Updated forecasts of COVID-19} \ \textbf{in the EU/EEA} \ \textbf{and UK}$ 

Importance: High

Dear Advisory Forum members,

Please find attached an updated set of forecasts of COVID-19 in EU/EEA for your review and feedback. Thank you for sending your comments to <a href="mailto:occurrent-sending-10.1.2e">occurrent-sending your comments to <a href="mailto:occurrent-sending-10.1.2e">occurrent-sending

Please note that these predictions are being reviewed technically by one modelling team in each Member State where we have direct contact. If you have further recommendations for modellers who can provide feedback from your country, please contact the e-mail address above.

Best regards,

Executive Office/ Governance



## European Centre for Disease Prevention and Control (ECDC) Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01

www.ecdc.europa.eu



## Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.